AC-1370对小鼠实验性感染的治疗效果。

The therapeutic efficacy of AC-1370 against experimental infections in mice.

作者信息

Obana Y, Nishino T, Tanino T

出版信息

J Antimicrob Chemother. 1985 Dec;16(6):727-34. doi: 10.1093/jac/16.6.727.

DOI:10.1093/jac/16.6.727

Abstract

The therapeutic efficacy of AC-1370, a new cephalosporin, was compared with that of cefoperazone in experimental infections in mice. For intraperitoneal infections caused by Escherichia coli and Klebsiella pneumoniae, the efficacy of AC-1370 was inferior to that of cefoperazone. On the other hand, AC-1370 was more potent than cefoperazone against pseudomonal infections. The MICs of AC-1370 against the test strains, however, were inferior or equivalent to those of cefoperazone. Serum and peritoneal exudate levels of AC-1370 in infected mice were more durable than those of cefoperazone. The relationship between AC-1370 and neutrophils was investigated. The efficacy of AC-1370 was more dependent on neutrophils than that of cefoperazone. AC-1370 did not enhance the neutrophil functions of migration and phagocytosis to any significant extent.

摘要

将新型头孢菌素AC - 1370的治疗效果与头孢哌酮在小鼠实验性感染中的治疗效果进行了比较。对于由大肠杆菌和肺炎克雷伯菌引起的腹腔感染，AC - 1370的疗效低于头孢哌酮。另一方面，AC - 1370在抗假单胞菌感染方面比头孢哌酮更有效。然而，AC - 1370对测试菌株的最低抑菌浓度低于或等同于头孢哌酮。感染小鼠血清和腹腔渗出液中AC - 1370的水平比头孢哌酮更持久。研究了AC - 1370与中性粒细胞之间的关系。AC - 1370的疗效比头孢哌酮更依赖于中性粒细胞。AC - 1370在很大程度上并未增强中性粒细胞的迁移和吞噬功能。